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Cellular immune response, specifically tumor infiltrating lymphocytes (TILs), has been 
correlated to survival in epithelial ovarian cancer; however, specific gene expression patterns 
for this response remain poorly understood. The objective of this research was to investigate 
the prognostic and biologic significance of immune-related gene expression in high grade 
serous ovarian cancer (HGSOC). To do so, a panel of immune related gene expression was 
evaluated in HGSOC utilizing The Cancer Genome Atlas (TCGA) and validated in an 
independent cohort of ovarian tumors. Based on the strong association with survival, the 
cohort was grouped into LCK (lymphocyte specific tyrosine kinase) high and non-LCK high 
tumors and profiles of gene expression and clinical information were obtained. We 
demonstrate that mRNA upregulation of LCK was correlated with the strongest improvement 
in survival of the genes investigated. When compared to previously validated metrics such as 
cytolytic activity score (CYT), LCK proved to be a more discerning prognosticator across 
tumor types available in the TCGA. In ovarian cancer, correlated gene enrichments were 
notable for chemokine and immunoglobin complex related genes, ie B cell related transcripts. 
Therefore, this research shows that LCK is a biomarker of prognostic and biological 
  
importance, potentially due to its ability to capture the genomic signature of cooperative T 
and B cell interaction. This provides essential support for further investigation into the role of 
tumor infiltrating B cells (TIL-B) and tertiary lymphoid structures (TLS), from which 
insights into this cooperation can be drawn. As ovarian cancer is the leading cause of death 
from gynecologic malignancy, such insights have the potential to not only offer important 
prognostic information but also may provide novel therapeutic approaches to the treatment of 
this deadly disease.  
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BACKGROUND  
Literature Review 
Immunogenicity of Ovarian Cancer 
There is growing evidence to support a pivotal role of the immune system in the pathogenesis 
of cancer; in high grade serous ovarian cancer (HGSOC) and other cancers the presence of 
high levels of tumor infiltrating lymphocytes (TILs) has been associated with improved 
progression free survival (PFS) and overall survival (OS) [1]–[7]. TIL infiltration of 
treatment naïve tumors was associated with a significantly improved median progression free 
(22.4 vs 5.8 months, p < 0.001) and overall survival (50.3 vs 18.0 months, p < 0.001) 
compared to tumors with no T-cells present [7]. Additionally, expression of alternative 
markers of activation of the immunoreactivity, including upregulation of programmed-death 
ligands 1 and 2 (PD-L1 and PD-L2), has also been shown to correlate with improved OS [8]. 
Recent publications reported a histotype-specific nature of immune infiltration and 
demonstrated the magnitude of survival benefit in ovarian cancer was dose dependent on 
CD8 positive TILs [9], [10].  
 
However, the use of TIL classification by immunohistochemistry (IHC) for clinical decision-
making currently remains in its early stages, as IHC can be time intensive and requires 
comparatively specialized pathology input. Additionally, while prognostic ability is useful, 
ideally biomarkers should also be relevant to predict response to therapy. For example, the 
use of PDL1 staining has emerged as an intuitive marker for prediction of response to 
immune checkpoint inhibitors, at least in some cancers. Immune checkpoint inhibitors are a 
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novel class of drugs which are monoclonal antibodies that block PD-1/PDL-1 and result in 
increased immune response to tumor. These drugs have revealed efficacy in 10-15% of 
heavily pretreated ovarian malignancies with some durable responses [11]–[15].  However, 
given the low response rates and significant toxicities of such therapies, studies aimed at 
identifying factors to provide more personalized prognostication for response to these 
therapies in particular are of utmost importance. However, the predictive accuracy of IHC 
markers to determine response to immune checkpoint therapy for ovarian cancer remains 
unknown, as many trials remain ongoing and have not yet reported translational endpoints.  It 
is worth mentioning that the reported response rates to PD1/PDL1 targeting drugs are not 
appreciably higher in clinical trials using PDL1 positivity by IHC as an eligibility criterion 
[26]. Given the difficulties presented with IHC analyses, investigation into genomic markers 
represents an exciting potential alternative, but have thus far yielded mixed results.  
 
Genomic Biomarkers in Ovarian Cancer 
The biological basis and the identification of reliable genomic markers with prognostic 
significance have proven elusive. Multiple studies have attempted to identify gene expression 
signatures and their predictive ability for clinical outcome, including overall survival, time to 
relapse or response to chemotherapy [16]–[21].  However, gene expression models have thus 
far been limited by complexity, often requiring large and heterogeneous gene signatures in 
order to demonstrate prognostic ability. For example, one study using an analysis of 68 
HGSOC samples validated a 115 gene signature, termed the Ovarian Cancer Prognostic 
Profile (OCPP) [21]. When attempting to classify included relevant genes by function, 17 
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different function groups were required and included both immune-related function, 
angiogenesis pathways, and cell-cell adhesion signaling related to tumor epithelial-
mesenchymal transition. Discrete biologic etiologies for predictive ability is limited with 
such heterogeneity.  
 
There are very few studies which used unsupervised classification approaches, thus prior 
classification has previously been subject to inherent bias in grouping determinations. 
Approaches to such unbiased categorization have been limited by sample size and by 
inclusion of heterogeneous histologic ovarian tumor subtypes [22]–[24]. Perhaps the most 
comprehensive of such unsupervised clustering research analyzed 285 samples, including 
both high grade serous and endometrioid tumors [16]. Optimal clustering of array data 
revealed six different molecular subtypes, which were clinically relevant as they grouped by 
histologic subtype and clinical outcome. However, each subtype displayed distinct levels of 
immune cell infiltration and reactive stroma gene expression signatures, making it difficult to 
determine driver biologic pathways. 
 
Based on these subtypes, the original publication of the ovarian cancer TCGA analysis 
attempted to categorize samples into more biologically based functional groups [25]. The 
investigators identified an “immunoreactive” group as one of the four subtypes of high-grade 
serous ovarian cancer based on transcriptional profiling.  In this analysis, T-cell chemokine 
ligands, CXCL11 and CXCL10, and the receptor, CXCR3, characterized the immunoreactive 
subtype. Unfortunately, there was no prognostic impact on survival associated with this 
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immunoreactive subtype [25].  There is a critical unmet need to establish reliable genomic 
biomarker(s) for this tumor immune response with utility in prognostication and stratification 
of untreated ovarian cancers. 
 
Genomic Prognostic Scoring Systems in Other Tumor Types 
Investigation of such genomic biomarkers can be informed by research in alternate tumor 
types and then applied to HGSOC. One well published genomic prognostic feature is the 
cytolytic activity score (CYT), a quantitative measure of immune cytolytic activity based on 
transcript levels of perforin (PRF1) and granzyme A (GZMA) [11]. These two molecules 
reflect the central mechanism for cytotoxic lymphocyte killing; perforin is responsible for the 
creation of pores within the target cell membrane which then allow for the entry of 
granzymes that cleave caspases and induce apoptosis. CYT has been shown to be a useful 
metric of cyototoxic activation and subsequent improved survival in multiple other tumor 
types [11], [26]–[28]. 
 
In pancreatic cancer, a study of expression data from 134 tumors available in The Cancer 
Genome Atlas (TCGA) revealed that CYT-high tumors exhibit increased expression of 
multiple immune checkpoint related genes, and, interestingly, were inversely correlated with 
genomic alterations, indicating that intrinsic oncogenic processes drive immune suppression. 
However, this analysis did not report a relationship of CYT score subsets to clinical outcome 
and prognosis [27]. Similarly, an analysis of CYT in colorectal cancer demonstrated that 
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CYT-high tumors were associated with high levels of activated T-cells but did perform 
subsequent analysis in order to report improved overall survival in this tumor subset[26]. 
 
The definition of cut-off points for CYT-high and CYT-low tumors is not standardized 
across tumor types. In the above literature regarding pancreatic cancer, CYT was defined as 
top 10 percentile compared to bottom 25th percentile [27]. In colorectal, the threshold for 
dichotomization was determined at multiple candidate cut-points and the cut-off point that 
gave the most significant results was chosen [26]. A meta-analysis, performed across tumor 
subtypes within the TCGA, including ovarian cancer, found very diverse levels of CYT 
across different cancer types. Results were not dichotomized or clustered and instead were 
correlated as a continuous variable to various markers of immunoreactivity, namely immune 
checkpoint molecules and TILs [28].  
 
CYT score has not been independently studied in ovarian malignancy; further description of 
this score specifically in HGSOC is needed. Additionally, based on the meta-analysis by 
Roufas et al, this score can serve as a benchmark against which other proposed genomic 
biomarkers can be evaluated. 
 
Preliminary Data 
To address this unmet need to establish genomic biomarkers in ovarian malignancy, we 
undertook a preliminary study in which we analyzed 535 high grade serous ovarian samples 
in the TCGA dataset using the cBioPortal platform, 520 of which had Affymetrix U133 
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microarray data available for mRNA analysis [25], [29], [30]. Analysis of the TCGA was 
performed investigating the upregulation of a panel of immune related genes including: 
CD3E, CD3D, CD2, CD4, Perforin 1 (PRF1), Granzyme A (GZMA), CD19, and CD20 
(MS4A1) and LCK (Figure 1). CD8A data was unavailable within the microarray. 
Progression free and overall survival data were collected for each of the above genes and 
compared in elevated and non-elevated samples. 
 
LCK (lymphocyte specific tyrosine kinase) was shown to have the strongest association with 
survival; patients with high LCK mRNA expression had a median progression free survival 
of 29.4 months, compared to 16.9 in those without high LCK expression (p=0.003). Patients 
with high LCK had significantly longer overall survival than non-LCK high with median 
overall survival time of 95.1 months and 44.5 months, respectively (p= 0.001). Only two 
other markers chosen were statistically significantly associated with survival and shown to 
have less dramatic prognostic differences. High expression of B-cell marker CD20 (MS4A1) 
was associated with survival, with median PFS of 27.2 months (p= 0.08) and overall survival 
of 86.1 months (p=0.02), while CD3E elevation had a significant association with PFS 
(p=0.016) but was not associated with OS (p=0.330). High expression of the other immune 
related genes tested above was not associated with survival. 
 
This stringent high criteria for mRNA expression in LCK was found in 23 (4%) of all cases 
(Figure 1). We also evaluated potential demographic, clinical, and pathological differences 
between LCK high and remaining samples (Table 1). The median age of the entire cohort 
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was 59 years old (30-89 years), and most patients were advanced stage (72.9 % stage IIIC, 
16.0% stage IV). No differences were detected between the two groups with respect to 
clinical characteristics, including age, race, ECOG performance status, clinical stage, and 
tumor grade. 
 
These data demonstrate LCK expression has the potential to be a clinically important 
prognostic indicator in ovarian malignancy. LCK likely broadly captures the 
immunoreactivity of a tumor and thus is a less heterogeneous biologic marker than those 
previously studied, which have included both immune pathways as well as cell adhesion 
signaling and/or angiogenic molecular indicators. This simplicity is valuable as it may be 
more easily evaluated to frame further biologic hypotheses, especially within the context of 
HGSOC response to treatment options which rely on this immunoreactivity, such as immune 
checkpoint inhibitors. 
 
Public Health Significance 
High grade serous ovarian cancer (HGSOC) is the leading cause of death from 
gynecologic malignancy, with over 22,000 cases per year in the United States and over 
14,000 deaths [31]. The high mortality rate is due to the fact the majority of ovarian cancer 
presents at advanced stage III/IV and has a high risk of recurrence despite initial response to 
traditional platinum based therapy. These patients are treated with a large and ever-
expanding amount of healthcare resources such as hospitalizations, surgical treatment, and 
chemotherapeutic regimens. Additionally, novel treatment options such as immune 
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checkpoint inhibitors, which leverage the immune-reactive nature of this malignancy, are 
rapidly expanding in use but are also currently nearly prohibitively expensive [32], [33].  
There is no currently available effective screening method for ovarian cancer, thus 
primary prevention options remain limited [34]. Public health interventions must focus 
instead on secondary prevention, with early detection and improved prognostication, as well 
as tertiary prevention to reduce morbidity and recurrence. The identification of relevant 
clinically applicable biomarkers will allow for better patient counseling regarding prognosis 
and more educated decision-making regarding treatment planning. Additionally, the potential 
for selection of treatment based on a biomarker predicted response has the promise to 
drastically improve both treatment selection and, consequently, treatment efficacy.  
The current study contributes meaningfully to this gap in knowledge. As IHC markers 
of immunogenicity have not yet proved clinically useful, the current study uses the known 
TIL correlation with survival, to delve more deeply into potential immune related gene 
expression biomarkers. We capitalize on preliminary data obtained by the current 
investigator, which identifies LCK as a particularly valuable biomarker. The current study 
provides essential validation of these findings and better characterization of LCK’s utility as 
compared to previously validated markers such as CYT score. 
 
Hypothesis, Research Question, Specific Aims or Objectives 
Tumor infiltrating lymphocytes (TILs) are correlated with better prognosis in high grade 
serous ovarian cancer (HGSOC); however, specific gene expression patterns for this response 
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remain poorly understood. There is a critical unmet need to establish such genomic 
biomarkers within this deadly gynecologic malignancy.  
Preliminary data demonstrates LCK correlates with both progression free and overall 
survival in available TCGA samples. Therefore, we hypothesized this prognostic ability of 
LCK would be validated by protein-expression as evaluated by IHC in an independent 
cohort of HGSOC samples. We additionally hypothesized LCK would prove to be a 
better predictor of survival than cytolytic activity score (CYT) in HGSOC.  
We investigated these independent hypotheses via the following specific aims:  
Aim 1: Validate the association between LCK and survival in an independent cohort 
of HGSOC samples via immunohistochemistry 
Aim 2: Compare the prognostic capability of LCK to previously validated CYT score 
within the TCGA 
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METHODS 
The high grade serous ovarian cancer (HGSOC) provisional data set from the TCGA was 
analyzed to explore the correlation between a panel of immune cell markers and clinical 
outcome [18]. For mRNA expression analysis, Affymetrix U133 microarray data was used 
and only samples for which these data were available included.  Samples were divided into 
“high expression” and “non-high expression” groups using the Cbioportal web interface, for 
the following markers: CD2, CD3E, CD3D, CD4, GZMA, PRF1, CD19, MS4A1 and LCK 
[19], [20] where high expression was defined as expression within the top 3% (1.86 SD). As 
described in the background, LCK was demonstrated to significantly predict both progression 
free and overall survival. The current study represents the subsequent analyses of this same 
data required to validate this finding and further explore the value of LCK as a prognostic 
biomarker.  
 
Aim 1: Validate the association between LCK and survival in an independent cohort of 
HGSOC samples via immunohistochemistry 
Study Design, Setting, and Study Population:  
LCK protein expression was determined via immunohistochemistry on an independent cohort 
of 72 ovarian cancer samples using a commercially available anti-LCK antibody 
(HPA003494, Sigma-Aldrich). Additionally, CD8 (T-cell marker) and CD20 (B-cell marker) 
immunohistochemistry staining was performed in this cohort (CD20:SAB5600082, Sigma-
Aldrich, CD8: CD8-4B11-L-CE, Leica Biosystems), and demographics and survival data 
were abstracted.  
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Additionally, IHC was performed across a range of benign and malignant serous neoplasms 
on an available tissue microarray (TMA). The TMA contained a spectrum of serous 
gynecological tissues, including normal fallopian tube epithelium obtained at the time of 
salpingo-oophorectomy for benign ovarian cystadenomas and high grade serous carcinomas. 
It included a total of 20 normal fallopian tube samples, 14 high grade ovarian serous 
carcinoma tissues, and 13 benign serous cystadenomas. Each tissue specimen was 
represented as 3 independent cores on the TMA. 
 
Data Collection and Analysis: 
A semi-quantitative IHC score was assigned and evaluated by the investigator, with 
confirmation by pathology collaborators including a senior gynecologic pathologist. LCK 
status of these samples was unknown, therefore all parties were initially blinded to outcome. 
For scoring purposes, tissue LCK+ lymphocytes staining was classified as none (0, average 
of one or less LCK+ lymphocyte), low (1, less than 10 LCK+ lymphocytes), medium (2, 
greater than 10 but less than 40 LCK+ lymphocytes), and high (3, greater than 40 LCK+ 
lymphocytes or multiple germinal centers). The same cut offs were used for CD8 and CD20 
positivity. The counts were averaged over 3 fields for independent pathology samples or 
averaged over the 3 cores for TMA samples. 
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Statistical Analysis 
IHC score comparison was performed using the Mann-Whitney U test with p<0.05 
considered significant. Spearman correlations were performed to assess the strength of 
association of LCK, CD20, and CD8. Strength of correlations analysis was performed using 
R version 3.4.1 package “cocor” [21]. 
 
The sample size was pre-defined by availability of tumor samples; there were 72 HGSOC 
samples available for analysis. TCGA data in preliminary analysis demonstrated an 
improvement in survival from 16.9 months to 29.4 months for those with high LCK 
expression. Therefore, we assumed a similar doubling of survival in our validation cohort. 
However, preliminary data used a very stringent definition (top 3%) of high LCK expression, 
and IHC analysis is unable to have this level of specificity or discriminatory capacity. 
Therefore, based on prior literature in other tumor types and the known immunogenicity of 
ovarian malignancy, we estimated that approximately 30% of tumors would be LCK-high 
using the much less stringent IHC scoring metric. At a significance level of 0.05, with this 
expected ratio of 30% and assumed doubling of median survival, the 72 samples available 
provided a 74% power to detect a difference between LCK-high and non-LCK-high tumors.  
 
Human Subject Samples and Data Considerations 
Patients included in this study are a subset of patients with HGSOC who sought treatment at 
The University of Texas MD Anderson Cancer Center (MDACC).  Eligibility required 
pathologic confirmation at MDACC and availability of sample tissue blocks within the 
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Gynecologic Oncology Tumor Bank. All patient samples were collected on a tissue banking 
protocol approved by MDACC Institutional Review Board (IRB) (LAB06-0412). The 
included 72 samples are a previously established sample subset available in the lab of Dr. 
Samuel Mok, who provided consent for their use for the current project. Clinical information 
for this subset of patients was also previously collected in Dr. Mok’s lab. 
 
The current analysis represents a retrospective IHC analysis of these blocks and correlation 
with clinical data, without additional patient contact or intervention. Therefore, this study did 
not involve any additional testing, treatment or biopsy procedures. Retrospectively, it would 
be impractical to obtain consent from patients who may be lost to follow-up, no longer in 
treatment or have died, therefore, the current study was performed under a waiver of 
informed consent.  
 
All data collected is confidential and used only for research purposes.  The data resides on 
the secure, password protected, 21CFR part 11 compliant database. Subjects were not 
identified by name during data entry and analysis.  Subject names do not appear in any report 
or paper related to the study. Only the investigator and collaborators (including PI, Dr Amir 
Jazaeri, and Dr. Samuel Mok) have access to the data. Unique study numbers have replaced 
the HIPAA identifiers in the analytical file. 
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Aim 2: Compare the prognostic capability of LCK to previously validated CYT score 
within the TCGA 
Study Design, Setting, and Study Population:  
Similar to preliminary data, the high grade serous ovarian cancer (HGSOC) provisional data 
set from The Cancer Genome Atlas was analyzed [18]. For mRNA expression analysis, 
complete RNA sequencing data, rather than Affymetrix microarray data, was used for 
analyses to be performed across 30 tumor types available in the TCGA. The following tumor 
types (project code and n=sample size) were included: adrenocortical carcinoma (ACC, 
n=92), bladder/urothelial (BLCA, n=412), breast invasive carcinoma (BRCA, n=1098), 
cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC, n=307), 
cholangiocarcinoma (CHOL, n=51), colon adenocarcinoma (COAD, n=461), esophageal 
carcinoma (ESCA, n = 185), glioblastoma multiforme (GBM, n=617), head and neck 
squamous cell carcinoma (HNSC, n=528), kidney renal clear cell carcinoma (KIRC, n=537), 
kidney renal papillary cell carcinoma (KIRP, n=291), acute myeloid leukemia (LAML, 
n=200), low grade glioma (LGG, n=516), liver hepatocellular carcinoma (LIHC, n=377), 
lung adenocarcinoma (LUAD, n = 585), lung squamous cell carcinoma (LUSC, n=504), 
mesothelioma (MESO, n=87), ovarian serous cystadenocarcinoma (OV, n=608), pancreatic 
adenocarcinoma (PAAD, n=185), pheochromocytoma and paraganglioma (PCPG, n=179), 
prostate adenocarcinoma (PRAD, n=500), rectum adenocarcinoma (READ, n=172), sarcoma 
(SARC, n=261), skin cutaneous melanoma (SKCM, n=470), stomach adenocarcinoma 
(STAD, n=443), testicular germ cell tumors (TGCT, n=150), thyroid carcinoma (THCA, 
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n=507), uterine corpus endometrial carcinoma (UCEC, n=560), uterine carcinosarcoma 
(UCS, n=57), and uveal melanoma (UVM, n=80).  
 
Data Collection and Analysis: 
For this analysis in each cancer the LCK-high expressing population (the top 10%) was 
compared to the LCK-low population (bottom 10% in expression). The definition of high and 
low expressing samples was broadened from the stringent top 3% used in the preliminary 
analysis to make results more generalizable to a broader population of ovarian malignancy.  
 
LCK prognostic capacity was compared to CYT, which has been previously defined [14]. 
Briefly, to calculate CYT score, total raw read counts per gene were converted to transcripts 
per million (TPM), which were calculated by dividing by the gene's maximum transcript 
length to provide a coverage depth estimate and scaling to sum to a total depth of 1e6 per 
sample. CYT was then calculated as the geometric mean of GZMA and PRF1 expression 
values in TPM. As dichotomization of CYT-high and CYT-low is nonstandardized across 
prior literature, we defined high and low CYT groups as top 10% and bottom 10% for 
comparison, in order to parallel the LCK definition most exactly.  
 
Statistical Analysis 
Descriptive statistics (n, percent, mean, standard deviation) were calculated to summarize 
patient demographics.  Cox regression and backwards stepwise regressions were performed 
to assess overall survival (OS) and progression free survival (PFS) for LCK gene expression 
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and dichotomized CYT groups. Correction for multiple comparisons was performed using 
Bonferroni method. Statistical analyses were performed using SAS 9.4 for Windows (SAS 
Institute Inc., Cary, NC).   
 
Human Subject Samples and Data Considerations 
To address this aim, analyses mirrored what was performed to provide the preliminary data. 
Specifically, the high grade serous ovarian cancer (HGSOC) provisional data set from The 
Cancer Genome Atlas was analyzed [18]. This is a publicly available dataset that is query-
able via the cBioPortal web interface [19], [20]. This cBioPortal for Cancer Genomics was 
originally developed at Memorial Sloan Kettering Cancer Center (MSK), and is hosted by the 
Center for Molecular Oncology at MSK. The software is available under an open source 
license and is maintained by a multi-institutional team, consisting of MSK, the Dana Farber 
Cancer Institute, Princess Margaret Cancer Centre in Toronto, Children's Hospital of 
Philadelphia, The Hyve in the Netherlands, and Bilkent University in Ankara, Turkey. 
 
The proposed analysis represents additional analysis of this publically available data, thus 
does not involve any HIPAA identifiers. No additional consent is required for data usage, 
apart from appropriate citation of data source in any subsequent manuscript publication.  
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Abstract:  
Objective: To investigate the prognostic and biologic significance of immune-related gene 
expression in high grade serous ovarian cancer (HGSOC).  
Methods:  Gene expression dependent survival analyses for a panel of immune related genes 
were evaluated in HGSOC utilizing The Cancer Genome Atlas (TCGA). Prognostic value of 
LCK (lymphocyte specific tyrosine kinase) was validated using immunohistochemistry 
(IHC) in an independent set of 72 HGSOC. Prognostic performance of LCK was compared 
to cytolytic score (CYT) using RNAseq across multiple tumor types. Differentially expressed 
genes in LCK high samples and gene ontology enrichment were analyzed. 
Results:  High pre-treatment LCK mRNA expression was found to be a strong predictor of 
survival in a set of 535 ovarian cancers. Patients with high LCK mRNA expression had a 
longer median progression free survival (PFS) of 29.4 months compared to 16.9 months in 
those without LCK high expression (p=0.003), and longer median overall survival (OS) of 
95.1 months versus 44.5 months (p= 0.001), which was confirmed in an independent cohort 
by IHC (p=0.04). LCK expression was compared to CYT across tumor types available in the 
TCGA and was a more significant predictor of prognosis in HGSOC. Unexpectedly, LCK 
high samples also were enriched in numerous immunoglobulin-related and other B cell 
transcripts.  
Conclusions: LCK is a better prognostic factor than CYT in ovarian and other cancers. In 
HGSOC, LCK high samples were characterized by higher expression of immunoglobulin and 
B cell related genes suggesting a cooperative interaction between tumor infiltrating T and B 
cells may correlate with better survival in this disease.  
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Introduction 
Ovarian cancer is the leading cause of death from gynecologic malignancy, with over 22,000 
cases per year in the United States and over 14,000 deaths [1]. The high mortality rate is due 
to the fact that the majority of ovarian cancer presents at advanced stage III/IV and has a high 
risk of recurrence despite initial response to traditional platinum based therapy. There is 
growing evidence to support a pivotal role of the immune system in the pathogenesis of 
cancer; in ovarian cancer and others the presence of high levels of tumor infiltrating 
lymphocytes (TILs) has been associated with improved PFS and OS [2]–[8]. However, this 
impact is in the context of a complex interplay between multiple aspects of the tumor 
microenvironment, as T cell type, location, and tumor stromal factors have all been shown to 
modify survival rates [5], [9]–[13].  
 
In the setting of this complexity, there is a need for reliable biomarker(s) with utility in 
prognostication and stratification of untreated ovarian cancers. One well published genomic 
prognostic feature is the cytolytic activity score (CYT), a quantitative measure of immune 
cytolytic activity based on transcript levels of perforin (PRF1) and granzyme A 
(GZMA)[14]. These two molecules reflect the central mechanism for cytotoxic lymphocyte 
killing; perforin is responsible for the creation of pores within the target cell membrane 
which allow for the entry of granzymes that cleave caspases and induce apoptosis. CYT has 
been shown to be a useful metric of cyototoxic activation and subsequent improved survival 
in multiple tumor types [14]–[17]. Therefore, the objective of this study was to investigate a 
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panel of immune-related genes to determine their prognostic ability and compare to these 
previously validated metrics.  
 
Materials and Methods 
TCGA Data Analysis 
To explore the correlation between a variety of immune cell markers and clinical outcome, 
the high grade serous ovarian cancer (HGSOC) provisional data set from the TCGA was 
analyzed [18]. Because all information from the TCGA is de-identified and publically 
available, informed consent by the study participants and approval of an ethics committee 
were unnecessary to perform this portion of the study. For mRNA expression analysis, 
Affymetrix U133 microarray data was used and only samples for which these data were 
available included.  Samples were divided into “high expression” and “non-high expression” 
groups using the Cbioportal web interface, for the following markers: CD2, CD3E, CD3D, 
CD4, GZMA, PRF1, CD19, MS4A1 and LCK [19], [20] where high expression was defined 
as expression within the top 3% (1.86 SD). Gene expression and enrichment analyses were 
performed using BRB-ArrayTools (Version 4.5.1) developed by Dr. Richard Simon and the 
BRB-ArrayTools Development Team.  Gene expression analysis was performed with 
p<0.001 cutoff for significance to guard against false discovery due to multiple comparisons 
and at least two-fold difference in the geometric mean of expression levels. 
 
Subsequent analysis of RNA sequencing data was performed across 30 tumor types available 
in the TCGA. The following tumor types (project code and n=sample size) were included: 
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adrenocortical carcinoma (ACC, n=92), bladder/urothelial (BLCA, n=412), breast invasive 
carcinoma (BRCA, n=1098), cervical squamous cell carcinoma and endocervical 
adenocarcinoma (CESC, n=307), cholangiocarcinoma (CHOL, n=51), colon adenocarcinoma 
(COAD, n=461), esophageal carcinoma (ESCA, n = 185), glioblastoma multiforme (GBM, 
n=617), head and neck squamous cell carcinoma (HNSC, n=528), kidney renal clear cell 
carcinoma (KIRC, n=537), kidney renal papillary cell carcinoma (KIRP, n=291), acute 
myeloid leukemia (LAML, n=200), low grade glioma (LGG, n=516), liver hepatocellular 
carcinoma (LIHC, n=377), lung adenocarcinoma (LUAD, n = 585), lung squamous cell 
carcinoma (LUSC, n=504), mesothelioma (MESO, n=87), ovarian serous 
cystadenocarcinoma (OV, n=608), pancreatic adenocarcinoma (PAAD, n=185), 
pheochromocytoma and paraganglioma (PCPG, n=179), prostate adenocarcinoma (PRAD, 
n=500), rectum adenocarcinoma (READ, n=172), sarcoma (SARC, n=261), skin cutaneous 
melanoma (SKCM, n=470), stomach adenocarcinoma (STAD, n=443), testicular germ cell 
tumors (TGCT, n=150), thyroid carcinoma (THCA, n=507), uterine corpus endometrial 
carcinoma (UCEC, n=560), uterine carcinosarcoma (UCS, n=57), and uveal melanoma 
(UVM, n=80). For this analysis in each cancer, the LCK-high expressing population (the top 
10%) was compared to the LCK-low population (bottom 10% in expression). This was 
compared to CYT which has been previously defined [14]. Briefly, total raw read counts per 
gene were converted to transcripts per million (TPM), which was calculated by dividing by 
the gene's maximum transcript length to provide a coverage depth estimate and scaling to 
sum to a total depth of 1e6 per sample. CYT was calculated as the as the geometric mean of 
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GZMA and PRF1 expression values in TPM, where similar high (top 10%) and low (bottom 
10%) groups were compared.  
 
Immunohistochemistry (IHC) 
LCK protein expression was performed using immunohistochemistry on an independent 
cohort of 72 ovarian cancer samples using a commercially available anti-LCK antibody 
(HPA003494, Sigma-Aldrich). Additionally, CD8 and CD20 immunohistochemistry staining 
was performed in this cohort (CD20:SAB5600082, Sigma-Aldrich, CD8: CD8-4B11-L-CE, 
Leica Biosystems), and demographics and survival data was abstracted. All tumor tissue 
samples were collected under a protocol approved by MD Anderson Cancer Center 
Institutional Review Board.  They were resected from the primary tumor site of previously 
untreated HGSOC patients with stage 3 and 4 diseases. A semi-quantitative IHC score was 
assigned by pathology collaborators including a senior gynecologic pathologist (C.P., M.S.), 
and as LCK status of the sample was not previously tested both pathologists were inherently 
blinded.  For scoring purposes tissue LCK+ lymphocytes staining was as none (0, average of 
one or less LCK+ lymphocyte), low (1, less than 10 LCK+ lymphocytes), medium (2, greater 
than 10 but less than 40 LCK+ lymphocytes), and high (3, greater than 40 LCK+ 
lymphocytes or multiple germinal centers). The same cut offs were used for CD8 and CD20 
positivity, and the counts were averaged over 3 fields for independent pathology samples.  
 
IHC was additionally performed across a range of benign and malignant serous neoplasms on 
a tissue microarray (TMA), where counts were averaged over the 3 cores. All tissue was 
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obtained under an IRB approved protocol at the University of Virginia, and the TMA 
contained a spectrum of serous gynecological tissues, including normal fallopian tube 
epithelium obtained at the time of salpingo-oophorectomy for benign ovarian cystadenomas 
and high grade serous carcinomas. A total of 20 normal fallopian tube samples, 14 high grade 
ovarian serous carcinoma tissues, and 13 benign serous cystadenomas were compared. Each 
tissue specimen was represented as 3 independent cores on the TMA.  
 
Statistical analysis 
Descriptive statistics (n, percent, mean, standard deviation) were calculated to summarize 
patient demographics.  Cox regression and backwards stepwise regressions were performed 
to assess OS and PFS for immune-related genes and dichotomized CYT groups. Statistical 
analyses were performed using SAS 9.4 for Windows (SAS Institute Inc., Cary, NC).  IHC 
score comparison was performed using the Mann-Whitney U test with p<0.05 considered 
significant. Spearman correlations assessed the strength of association of LCK, CD20, and 
CD8. Strength of correlations analysis was performed using R version 3.4.1 package “cocor” 
[21]. 
 
Results 
High LCK expression predicts improved survival in HGSOC 
A total of 535 high grade serous ovarian samples in the TCGA dataset were included using 
the cBioPortal platform, 520 of which had Affymetrix U133 microarray data available for 
mRNA analysis [18]–[20]. Analysis of the TCGA was performed investigating the 
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upregulation of immune related genes including CD3E, CD3D, CD2, CD4, Perforin 1 
(PRF1), Granzyme A (GZMA), CD19, and CD20 (MS4A1) and LCK (Figure 1). Of note, 
CD8A data were unavailable within the TCGA microarray dataset. High LCK mRNA 
expression was present in 23 (4%) of all cases (Figure 1). Progression free and overall 
survival data were collected for each of the above genes and compared in elevated and non-
elevated samples. LCK was shown to have the strongest association with survival; patients 
with high LCK mRNA expression had a median progression free survival of 29.4 months, 
compared to 16.9 in those without high LCK expression (p=0.003). Similarly, patients with 
high LCK had significantly longer overall survival than non-LCK high with median overall 
survival time of  95.1 months and 44.5 months respectively (p= 0.001). As expected, LCK 
mRNA high samples also had significantly higher LCK protein levels as determined by 
reverse phase protein arrays (RPPA).  Only two other markers within the panel were 
statistically significantly associated with survival and were shown to have less dramatic 
prognostic differences. Specifically, high expression of B-cell marker CD20 (MS4A1) was 
associated with survival, with median PFS of 27.2 months (p= 0.08) and overall survival of 
86.1 months (p=0.02), while CD3E elevation had a significant association with PFS 
(p=0.016) but was not associated with OS (p=0.330). High expression of the other immune 
related genes tested above was not associated with survival. 
 
To examine if high LCK expression was simply a marker of high levels of tumor infiltrating 
lymphocytes (TIL), we compared the levels of CD3 and TCR related transcripts in LCK high 
samples. We also evaluated potential demographic, clinical, and pathological differences 
25 
 
between LCK high and remaining samples (Table 1). The median age in the entire cohort 
was 59 years old (30-89 years), and most patients were advanced stage (72.9 % stage IIIC, 
16.0% stage IV). No differences were detected between the two groups with respect to 
clinical characteristics, including age, race, ECOG performance status, clinical stage, and 
tumor grade. LCK expression was correlated with high expression of CD3 and TCR related 
transcripts, but as described above LCK had improved discriminatory prognostic ability than 
these markers alone.  
 
 Given the dramatic improvement in survival demonstrated in LCK-high samples, the 
influence of other established prognostic factors was tested in a Cox multivariable model that 
included LCK status, age, race (white vs other), stage, grade, and ECOG status. LCK status 
(p=0.021, HR=0.508) and race (p=0.024, HR = 0.657) were independent predictors of 
survival, ie reduced the risk of progression event. Additionally, LCK mRNA level improved 
OS (p=.001; HR=.315), as did race (p=.038; HR=.676) while age (p<.001; HR=1.026) 
increased the risk of death event. 
 
High LCK does not correlate to increased mutation number 
Non-synonymous somatic mutations in malignancies can lead to expression of “neo-
epitopes” and hence increased potential immunogenicity, thus the relationship between LCK 
levels and number of somatic mutations in high grade serous ovarian cancer samples was 
evaluated. High mutation load, as defined by mutation count > 100, was present in 18 out of 
520 tumors with sequencing data available (3.5%). To determine a possible relationship 
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between mutational load and LCK expression, the number of somatic mutations in LCK high 
samples was compared to that of non-LCK high tumors. This revealed no significant 
difference in mutation load or copy number alteration based on LCK expression status 
(Figure 1).  In fact, in the LCK high samples, there was only one tumor with a mutation 
count greater than 100 (4.3% of the LCK high group).  
 
LCK is a more significant prognostic predictor than CYT in ovarian cancer and many other 
malignancies 
For this analysis, the definition of LCK high samples was liberalized (top 10%) and survival 
was compared to low LCK (bottom 10%) within the TCGA in order to reduce selection bias 
due to small numbers of LCK high/low cases. The median OS in the LCK high group was 
52.6 months, as compared to 35.3 months in the LCK low group (p=0.00898). Similar 
dichotomization of CYT, a measure of transcript levels of perforin (PRF1) and granzyme A 
(GZMA), was performed; samples were grouped by CYT score into highest and lowest 10%. 
CYT did not predict survival, with median OS was 49.4 and 52.8 months in high and low 
cohorts respectively (p = 0.664). Kaplan-Meier curves can be found in Figure 2.  
 
This analysis was performed for 30 tumor types available in TCGA (Table 2). Of these 30 
cancer types, CYT was a significant predictor of overall survival in 5 cancers including: 
breast invasive carcinoma (BRCA, p=0.00293), cervical carcinoma (CESC, p = 0.0121), low 
grade glioma (LGG, p = 0.0112), sarcoma (SARC, p = 0.0323), and cutaneous melanoma 
(SKCM, p = 0.00509). The LCK high group also had statistically significant improved 
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survival in these subtypes (BRCA p=0.0546, CESC p= 0.000748, LGG p = 0.0269, SARC p 
= 0.0166, and SKCM p =0.0271). Interestingly, high LCK expression also had improved 
overall survival in an additional 3 cancer subtypes, namely: ovary as described above, head 
and neck squamous carcinoma (HNSC, p = 0.0496), and uterine carcinosarcoma (UCS, p = 
0.0358). Therefore, LCK was a more discerning predictor in tumor types where CYT was 
predictive of OS, and it was additionally prognostic in a further subset of tumor types where 
CYT was not. 
 
LCK protein expression independently confirms impact on prognosis 
In order to determine if there was concordance between high LCK mRNA and protein 
expression we investigated LCK protein levels in samples designated as LCK-high by 
mRNA expression in the TCGA cohort using reverse phase protein arrays (RPPA).  As 
expected, the LCK-high mRNA samples also expressed significantly higher levels of LCK 
protein. We also used an independent validation cohort of 72 high grade serous ovarian 
cancer samples with available clinical data to compare LCK protein expression using IHC 
with CD8, and CD20 (markers of cytotoxic Tlymphocytes and B-cells, respectively). This 
analysis confirmed that LCK expression was specific to tissue lymphocytes and that there 
was no confounding LCK expression by normal epithelial or by tumor cells. Furthermore, 
survival analysis revealed that only high LCK staining significantly increased overall 
survival, with median survival for high LCK staining of 40.5 months compared to 27.0 
months (p=0.04, Figure 3). Neither LCK intensity nor LCK distribution (focal or diffuse) 
resulted in further stratification of the impact of LCK on survival.  
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Transcriptional profile differs in LCK high samples 
Given the prognostic importance of high LCK expression, we used the availability the U133 
microarray data as part of the TCGA dataset to evaluate gene expression differences between 
LCK-high expressing (n=23) and remaining samples (n=496).  This analysis revealed 291 
differentially expressed transcripts (at a statistical cut-off of P<0.001 and at least twofold 
change). As expected, LCK-high samples were characterized by higher expression of many 
transcripts associated with T cell function (Appendix A).  For example, CD2, CD3, TRBC1, 
GZMA, GZMB, TRAC, and several HLA class I and II transcripts were all significantly 
higher expressed in LCK high samples.  The greatest fold change was observed for 
Chemokine (CXC motif) ligand  9 (CXCL9, also known as chemokine induced by interferon 
γ (MIG)) with 15.64 higher expression level in the LCK high samples.  Given that LCK is a 
canonical T lymphocyte signaling molecule, it was surprising to find that many B 
lymphocyte/plasma cell related transcripts including many immunoglobulin genes (e.g. 
IGHD, IGHM, IGKC, IGLJ3, IGLC1, and IGLV1-44) were also enriched in the LCK-high 
samples (Appendix A). Interestingly, CXCL13 (also known as B lymphocyte 
chemoattractant (BLC)) was one of the chemokines enriched in LCK high samples (7.7 fold). 
 
We next performed gene ontology enrichment analysis (Table 3), where genes are defined 
into subsets based on functional characteristics allowing for the biologic profile of the gene 
set to be obtained. This analysis confirmed that LCK high samples were significantly 
enriched in B cell function and activity, as demonstrated by the highest observed-to-expected 
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ratios in the “immunoglobulin complex circulating” gene ontology term (enrichment score: 
46.41). In terms of molecular function, MHC II receptor activity was most closely correlated 
with an enrichment score of 41.73, followed by C-C chemokine binding (29.8), and this was 
mirrored in the biologic process analysis where MHC class II protein complex assembly had 
the greatest enrichment (32.44, Table 3).  
 
Given the enrichment of B-cell transcripts in LCK high samples, we also investigated the 
presence of tertiary lymphoid structures (TLS) in the independent cohort of 72 HGSOC 
samples. TLS represent transient colocalization of lymphoid cells in non-lymphoid tissues; 
the presence of TLS has been described in multiple solid tumor types and is felt to influence 
local and potentially systemic anti-cancer response. We found that LCK expression by IHC 
was moderately correlated with TLS (Spearman correlation: 0.53, p= <0.0001). Proportional 
hazards regression analysis was performed including both TLS and LCK as predictors of OS, 
and both were significant independent predictors of survival (HRTLS = 4.1, p=0.004, HRLCK= 
3.8, p=0.005). Finally, consistent with our mRNA expression analysis, there was moderate 
correlation between LCK, CD20, CD8 staining, but there was no evidence of any difference 
in strength of correlation between pairs of these markers (95% CI -0.18-0.28 for LCK/CD8 
vs LCK/CD20 and 0.14-0.31 for CD20/CD8 vs LCK/CD8).   
 
Given the prognostic significance of LCK positive lymphocytes in HGSOC, we next sought 
to determine if the abundance of such lymphocytes differed between normal fallopian tube 
epithelium (tissue of origin for the vast majority of HGSOC), benign serous neoplasms, and 
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HGSOC. LCK expression was evaluated by IHC in a TMA consisting of 20 normal fallopian 
tube samples, 13 serous cystadenomas, and 14 HGSOC samples.  We observed higher LCK 
expression in the malignant samples than in their benign counterparts (p=0.023, Appendix 
B). However, LCK expressing lymphocytes were present (albeit at lower prevalence) among 
normal fallopian tube epithelium samples, suggesting a possible surveillance or a tissue 
resident function.   
 
Discussion 
The immunogenicity of EOC has been well documented, with extensive literature 
demonstrating the presence of tumor infiltrating lymphocytes in ovarian tumors and their 
prognostic significance [2]–[8]. However, the biological basis and the identification of 
reliable markers for this prognostic significance have proven elusive.  The original 
publication of the ovarian cancer TCGA analysis identified an “immunoreactive” group as 
one of the four subtypes of high grade serous ovarian cancer based on transcriptional 
profiling.  However, there was no prognostic impact on survival associated with this 
immunoreactive subtype [18].  Recent publications have reported a histotype-specific nature 
of immune infiltration and have demonstrated that the magnitude of survival benefit in 
ovarian cancer was dose dependent on CD8 positive TILs [22], [23]. However, the use of 
TIL for clinical decision making currently remains in its early stages, and investigation into 
genomic markers have yielded mixed results.  
 
31 
 
The need for a robust, reproducible, and immune-related biomarker in HGSOC is further 
highlighted by the emerging data on immune checkpoint blockers resulting in response rates 
of 10-15% in heavily pretreated patients [14], [24]–[27].  Given the low response rates and 
significant toxicities of such therapies, studies aimed at identifying factors to provide more 
personalized prognostication for immune response in particular are of utmost importance.  
The use of PDL1 staining has emerged as a convenient and intuitive marker for prediction of 
response to immune checkpoint inhibitors, at least in some cancers.  However, the predictive 
accuracy of this marker for ovarian cancer remains unknown.  It is worth mentioning that the 
response rates to PD1/PDL1 targeting monoclonal antibodies is not appreciably higher in 
clinical trials that used PDL1 positivity by IHC as an eligibility criterion [26].  
 
The current study demonstrates high LCK expression identifies a small subset of high grade 
serous ovarian cancers with better PFS and OS following treatment with standard frontline 
platinum-taxane adjuvant chemotherapy. LCK is an attractive biomarker as it plays a central 
functional role in T-cell signaling. The T-cell receptor (TCR) is composed of an antigen 
recognition subunit (TCRαβ) as well as three signaling subunits (CD3) [28]. TCR-CD3 
engagement with antigen induces phosphorylation by LCK, which then triggers downstream 
signaling cascades leading to antigen specific T-cell immune response. Additionally, mice 
lacking LCK develop profound T cell deficiency [29]. Therefore, LCK is central to effective 
and specific T-cell response, including to tumor antigen. However, LCK is demonstrated 
herein to have greater discriminatory prognostic ability than previously validated metrics of 
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T cell function such as CYT, which suggests it may capture additional facets of tumoral 
immune response such as B cell activity. 
 
The impact of B cell infiltrates in ovarian malignancy is less clear than their T-cell 
counterparts, though they have been shown to similarly be associated with improved survival 
[12], [13], [30]. The role of B cells has been supported by prior analysis of the TCGA, which 
demonstrated improved survival with B-cell gene expression signatures in high grade serous 
ovarian cancer [31]. The causality and mechanism of the herein reported correlation between 
LCK and B cell signatures remains to be determined. Prior literature suggests B cells may 
induce the maturation of dendritic cells making them competent for T-cell activation, and 
preclinical studies demonstrate depletion of B cells in a mouse model results in decreased 
expression of the degranulation marker CD107 on CD8+ T cells, suggesting impaired 
cytotoxic response [32], [33]. Interestingly, LCK has also been implicated in B-cell signaling 
at least in a minor but important B-cell subset, namely B-1 cells. These cells are found 
predominantly in peritoneal and pleural cavities, which are notably the primary location of 
ovarian cancer spread, and are characterized by deficient B-cell receptor (BCR) signaling 
[30], [31]. In future studies we plan to further investigate the potential prognostic 
significance of B1-cells and their LCK expression in HGSOC. 
 
The limitations of the current research include small sample size, specifically due to the 
stringent criteria of top 3%; the low number of LCK high tumors within the TCGA limits the 
power of this analysis, specifically for gene enrichment and ontology. However, for all 
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subsequent analyses, more liberal definitions of LCK high tumors were used, including top 
10% for comparison with CYT and pathologic criteria for IHC in the independent cohort. 
Therefore, the consistency of the association between LCK and survival lends strength to this 
conclusion. For the comparison to CYT, the high and low cohorts were defined arbitrarily, as 
has been done in other analyses; for example, significance of CYT in pancreas defined top 
decile and compared to bottom quartile resulting in a difference in significance level [17].  
 
In summary, this study demonstrates high LCK expression is associated with significantly 
longer survival than non-high LCK tumors, and was found to be a more significant predictor 
of prognosis than the previously validated cytolytic activity score (CYT) across tumor types, 
including HGSOC. LCK high samples demonstrated evidence of enriched B cell infiltration 
and function raising the possibility a cooperative interaction between tumor infiltrating T and 
B cells is correlated with better survival in this disease. Further research is needed to better 
elucidate the causality and mechanism of this correlation. 
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CONCLUSION 
In this study, we sought to establish genomic biomarkers in ovarian malignancy 
which capture the known immunogenicity of this tumor type and its relationship to 
prognosis. We utilized the Cancer Genome Atlas (TCGA) to demonstrate high LCK mRNA 
expression was a strong predictor of survival in a set of 535 ovarian cancers. Patients with 
high LCK mRNA expression had a longer median progression free survival (PFS) and 
overall survival (OS). We then confirmed this association of LCK with survival in an 
independent cohort, and importantly used less stringent cut offs for definition of high 
expressing tumors which allows our findings to be generalized to a greater subset of ovarian 
malignancy. Additionally, LCK expression was compared to a previously validated metric, 
cytolytic activity score (CYT), in order to determine their respective prognostic capacity. 
Across tumor types available in the TCGA, LCK was a more significant predictor of 
prognosis; LCK was a more discerning predictor in tumor types where CYT was predictive 
of OS, and it was additionally prognostic in a further subset of tumor types where CYT was 
not in HGSOC.  
 
In an attempt to generate alternate hypotheses about the mechanism for the improved 
prognostic ability of LCK, we used the ovarian cancer TCGA dataset to evaluate gene 
expression differences between LCK-high expressing and the remaining samples. Given that 
LCK is a canonical T lymphocyte signaling molecule, it was surprising to find many B 
lymphocyte/plasma cell related transcripts including many immunoglobulin genes were also 
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enriched in the LCK-high samples. This research suggests a cooperative interaction between 
tumor infiltrating T and B cells may correlate with better survival in this disease, and this 
relationship is captured by LCK expression and is not reflected by other metrics which are 
specifically T-cell focused such as CYT. 
 
To date, most studies evaluating the prognostic significance of TILs have 
concentrated on T cells, while less attention has been devoted toward TIL-B cells. In ovarian 
cancer there is conflicting evidence on the association between B-cells and survival. TIL-B 
cells may function to present tumor antigen to cytotoxic T cells or other immune effector 
cells, and plasma cells may secrete antibodies aiding the immune response against tumor 
cells. Alternatively, TIL-B subsets may function to suppress T cell anti-tumor responses (as 
in Bregs) or promote tumor progression by nurturing an inflammatory microenvironment. 
Therefore, it will be important to build upon the data presented herein to investigate these B-
cell signatures within the TCGA. Additionally, in our independent cohort, further 
investigation of tertiary lymphoid structures, which may serve as an immunohistochemical 
and pathologic marker of T and B cell cooperation, should be reviewed.  
 
The limitations of the current research include small sample size, specifically due to the 
stringent criteria of top 3%; the low number of LCK high tumors within the TCGA limits the 
power of this analysis, specifically for gene enrichment and ontology. However, for all 
subsequent analyses, more liberal definitions of LCK high tumors were used, including top 
10% for comparison with CYT and pathologic criteria for IHC in the independent cohort. 
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Therefore, the consistency of the association between LCK and survival lends strength to this 
conclusion. For the comparison to CYT, the high and low cohorts were defined arbitrarily, 
however this is similar to the approach in other analyses.  
 
In summary, high LCK expression is a better prognostic marker than the previously validated 
cytolytic activity score (CYT) across tumor types, which we argue is due to its ability to 
capture T and B cell cooperation, given that LCK high samples demonstrated evidence of 
enriched B cell infiltration and function. Further research is needed to better elucidate the 
causality and mechanism of this correlation. Improved understanding of these relationships 
may offer valuable therapeutic approaches for the treatment of ovarian cancer, particularly in 
patients with drug or immune therapy resistant disease. 
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TABLES 
Table 1: Demographics by LCK Expression Level 
Total Cohort† 
520 
LCK High* 
n=23 
Non-LCK High 
n=497 
 
Characteristic   p-value 
Age (median) 40-78 (58) 30-89 (59) 0.837 
ECOG Performance    
0.633 
   0 4 69 
   1 3 72 
   2 2 21 
   3 0 4 
Unknown 14 331 
Stage   
0.134 
   I 1 15 
   II 3 25 
   IIIA,B 3 28 
   IIIC 13 366 
   IV 3 80 
Unknown 0 4 
Grade   
0.552 
   1 0 5 
   2 3 61 
   3 19 419 
   Unknown 1 12 
Race/Ethnicity   
0.4696 
   Asian 1 14 
   Black 0 23 
   Hispanic 1 7 
   White 20 433 
   Other/Unknown 1 20 
†520 patients included from a total of 535 samples available 
*LCK (lymphocyte specific tyrosine kinase) high: expression >1.86SD within TCGA ovarian serous 
cystadenocarcinoma study (TCGA, provisional). 
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Table 2: Survival Analyses Comparing the Prognostic Ability of LCK and CYT 
Cancer 
subtype1 
LCK Cytolytic Activity Score (CYT) 
 
Median OS 
bottom 10% 
(months) 
Median OS 
top 10% 
(months) 
P value 
Median OS 
bottom 10% 
(months) 
Median OS 
top 10% 
(months) 
P value 
ACC NA NA 0.818 NA NA 0.990 
BLCA NA 94.3 0.254 NA NA 0.506 
BRCA 90.4 132 0.055 84.5 NA 0.003 
CESC 19.4 NA 0.001 136 NA 0.012 
CHOL 24.7 NA 0.870 9.03 NA 0.642 
COAD NA NA 0.363 NA NA 0.863 
ESCA 42.1 26.1 0.930 26.1 16.1 0.617 
GBM 13.2 12.5 0.623 13.2 10.6 0.295 
HNSC 85.7 161.9 0.050 28.7 58.7 0.109 
KIRC NA 66 0.497 NA 73 0.473 
KIRP NA NA 0.232 NA 98 0.591 
LAML 12.2 10.1 0.118 26.4 10.2 0.084 
LGG 63 63.8 0.027 81.1 52.6 0.011 
LIHC NA 54.1 0.865 59.7 56.2 0.763 
LUAD 48.5 87.2 0.368 49.7 43.1 0.664 
LUSC 74.1 56 0.603 74.1 61.9 0.918 
MESO 17.6 13.8 0.584 25.2 13.8 0.959 
OV 35.3 52.6 0.009 52.8 49.4 0.664 
PAAD NA 23.4 0.687 21.7 50.1 0.973 
PCPG NA NA 0.429 NA NA 0.317 
PRAD NA NA 0.304 NA NA 0.893 
READ NA NA 0.317 NA NA 0.221 
SARC 35.4 NA 0.017 41.2 NA 0.032 
SKCM 54.3 164.3 0.027 58.9 164.3 0.005 
STAD 58.2 22.3 0.857 73.2 NA 0.936 
TGCT NA NA 0.317 NA NA 0.289 
THCA NA NA 0.631 NA NA 0.659 
UCEC NA NA 0.221 NA NA 0.263 
UCS 22.8 30.4 0.036 31.6 NA 0.804 
UVM NA NA 0.808 NA NA 0.806 
 
Median overall survival in high LCK expression and low LCK expression as compared to 
high and low CYT score. High and low groups are defined as top 10% and bottom 10% 
respectively.  
 
 
1 The following tumor types (project code and n=sample size) were included: adrenocortical carcinoma (ACC, 
n=92), bladder/urothelial (BLCA, n=412), breast invasive carcinoma (BRCA, n=1098), cervical squamous cell 
carcinoma and endocervical adenocarcinoma (CESC, n=307), cholangiocarcinoma (CHOL, n=51), colon 
adenocarcinoma (COAD, n=461), esophageal carcinoma (ESCA, n = 185), glioblastoma multiforme (GBM, 
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n=617), head and neck squamous cell carcinoma (HNSC, n=528), kidney renal clear cell carcinoma (KIRC, 
n=537), kidney renal papillary cell carcinoma (KIRP, n=291), acute myeloid leukemia (LAML, n=200), low 
grade glioma (LGG, n=516), liver hepatocellular carcinoma (LIHC, n=377), lung adenocarcinoma (LUAD, n = 
585), lung squamous cell carcinoma (LUSC, n=504), mesothelioma (MESO, n=87), ovarian serous 
cystadenocarcinoma (OV, n=608), pancreatic adenocarcinoma (PAAD, n=185), pheochromocytoma and 
paraganglioma (PCPG, n=179), prostate adenocarcinoma (PRAD, n=500), rectum adenocarcinoma (READ, 
n=172), sarcoma (SARC, n=261), skin cutaneous melanoma (SKCM, n=470), stomach adenocarcinoma 
(STAD, n=443), testicular germ cell tumors (TGCT, n=150), thyroid carcinoma (THCA, n=507), uterine corpus 
endometrial carcinoma (UCEC, n=560), uterine carcinosarcoma (UCS, n=57), and uveal melanoma (UVM, 
n=80). 
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Table 3: Gene Ontology Enrichment in selected subset (LCK high)  
Cellular Component    
GO ID GO Term Observed in Expected in Observed/ 
selected subset selected subset Expected* 
GO:0042571 immunoglobulin complex, circulating 7 0.15 46.41 
GO:0019814 immunoglobulin complex 7 0.22 32.48 
GO:0042612 MHC class I protein complex 6 0.26 23.2 
GO:0061702 inflammasome complex 6 0.3 19.89 
GO:0042101 T cell receptor complex 6 0.39 15.47 
Molecular Function  
   
GO:0032395 MHC class II receptor activity 7 0.17 41.73 
GO:0019957 C-C chemokine binding 5 0.17 29.8 
GO:0046977 TAP binding 6 0.22 26.82 
GO:0019865 immunoglobulin binding 6 0.24 24.76 
GO:0004950 chemokine receptor activity 8 0.34 23.84 
GO:0001637 G-protein coupled chemoattractant receptor 
activity 
8 0.34 23.84 
GO:0023026 MHC class II protein complex binding 6 0.26 22.99 
GO:0019956 chemokine binding 6 0.28 21.46 
GO:0045236 CXCR chemokine receptor binding 6 0.3 20.12 
GO:0023023 MHC protein complex binding 6 0.3 20.12 
Biological Process  
   
GO:0002399 MHC class II protein complex assembly 5 0.15 32.44 
GO:0046113 nucleobase catabolic process 5 0.18 27.8 
GO:0002396 MHC protein complex assembly 5 0.18 27.8 
GO:0010818 T cell chemotaxis 9 0.39 23.35 
GO:0002480 antigen processing and presentation of 
exogenous peptide antigen via MHC class I, 
TAP-independent 
5 0.23 21.62 
GO:0090026 positive regulation of monocyte chemotaxis 7 0.36 19.46 
GO:0010819 regulation of T cell chemotaxis 5 0.26 19.46 
GO:1901623 regulation of lymphocyte chemotaxis 9 0.49 18.44 
GO:0036037 CD8-positive, alpha-beta T cell activation 5 0.31 16.22 
* Observed/Expected <15.0 not reported 
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FIGURES 
Figure 1: TCGA Analysis of Immune-related Gene Expression 
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Figure 2: Kaplan Meier Analysis Comparing Prognostic Ability of LCK and CYT
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Figure 3: LCK Expression and Survival Analysis in an Independent Cohort
  
44 
 
APPENDICES 
Appendix A:  Top Overexpressed Genes in LCK High Samples 
Symbol Name 
Geometric 
mean of 
intensities in 
class 1* 
Geometric 
mean of 
intensities in 
class 2** 
  
Fold changeᵻ 
Parametric 
p-value 
FDR 
CXCL9 
chemokine (C-X-C motif) 
ligand 9 55.65 870.35 15.639712 < 1e-07 < 1e-07 
IGLC1 
immunoglobulin lambda 
constant 1 (Mcg marker) 186.45 1984.25 10.642263 < 1e-07 < 1e-07 
IGHM 
immunoglobulin heavy 
constant mu 26.53 221 8.3301922 < 1e-07 < 1e-07 
IGKC 
immunoglobulin kappa 
constant 26.11 226.8 8.6863271 < 1e-07 < 1e-07 
JCHAIN 
joining chain of multimeric 
IgA and IgM 25.76 217.56 8.4456522 < 1e-07 < 1e-07 
IGKC 
immunoglobulin kappa 
constant 27.05 221.33 8.1822551 < 1e-07 < 1e-07 
CXCL13 
chemokine (C-X-C motif) 
ligand 13 18.99 151.74 7.9905213 < 1e-07 < 1e-07 
IGHM 
immunoglobulin heavy 
constant mu 16.18 113.07 6.9882571 < 1e-07 < 1e-07 
TRBC1 T cell receptor beta constant 1 32.03 208.74 6.5170153 < 1e-07 < 1e-07 
IGLJ3 
immunoglobulin lambda 
joining 3 23.3 154.25 6.6201717 < 1e-07 < 1e-07 
IGKC 
immunoglobulin kappa 
constant 103.1 681.32 6.6083414 < 1e-07 < 1e-07 
CCL5 
chemokine (C-C motif) ligand 
5 27.65 175.54 6.3486438 < 1e-07 < 1e-07 
TRBC1 T cell receptor beta constant 1 31.07 187.03 6.0196331 < 1e-07 < 1e-07 
IGLC1 
immunoglobulin lambda 
constant 1 (Mcg marker) 19.22 109.64 5.7044745 < 1e-07 < 1e-07 
CD2 CD2 molecule 24.16 129.36 5.3543046 < 1e-07 < 1e-07 
IGLJ3 
immunoglobulin lambda 
joining 3 13.85 71.54 5.165343 < 1e-07 < 1e-07 
CD8A CD8a molecule 16.17 82.27 5.0878169 < 1e-07 < 1e-07 
CD3D 
CD3d molecule, delta (CD3-
TCR complex) 34.53 175.11 5.0712424 < 1e-07 < 1e-07 
IGLV1-44 
immunoglobulin lambda 
variable 1-44 14.17 72.32 5.1037403 < 1e-07 < 1e-07 
*Class1 = non-LCK high ** Class2 = LCK high 
ᵻ Fold change < 5.0 are not reported 
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Appendix B: LCK Expression in Benign and Malignant Tissue 
 
(A) LCK expression levels by immunohistochemistry staining score. Staining score defined 
as: 0=none, 1=low, 2= medium, 3 = high. (B-D) Representative examples of varying LCK 
expression by immunohistochemistry. B: LCK high expression in high grade serous ovarian 
cancer. C: non LCK high expression (low) in high grade serous ovarian cancer. D: Moderate 
LCK expression in normal fallopian tube (medium). 
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